Receive Breaking News updates as they occur
(Reuters) - Drugmaker AbbVie Inc said it will buy Pharmacyclics Inc , the maker of blockbuster cancer drug Imbruvica, for about $21 billion to broaden its oncology drugs pipeline. The deal gives AbbVie access to Pharmacyclics' cancer drugs portfolio, lessening the Chicago-based company's dependence on its rheumatoid arthritis drug Humira that accounts for most of its sales. The transaction follows AbbVie's failed $55 billion bid to buy Dublin-based Shire Plc last October after the United States took steps to deter tax-lowering deals. Pharmacyclics said earlier it expects sales of Imbruvica, which is approved in more than 40 countries and has U.S. approvals for four forms of blood cancer, to touch $1 billion in the United States this year.
BOSTON (AP) — Jurors in the Boston Marathon bombing trial spent the first day of testimony listening to heartbreaking stories from victims and watching graphic videos of blown-off limbs, bloody sidewalks and chaos after the 2013 attack.
BEIJING (AP) — China said Thursday it will boost defense spending by 10.1 percent, a smaller rise than last year but in line with large annual increases that have drawn concern among the country's neighbors over Beijing's military and territorial ambitions.